Crawford’s First Business After Confirmation: Brief Senators On Mifeprex
Executive Summary
FDA Commissioner Lester Crawford's first business following his confirmation was to brief members of Congress about reports of deaths in patients using Danco Laboratories' abortifacientMifeprex
You may also be interested in...
Von Eschenbach’s Commissioner Debut May Be Release Of Safety Report
One of Andrew von Eschenbach's first major steps as FDA commissioner is likely to be release of the agency task force response to the Institute of Medicine's recommendations to improve drug safety oversight
Von Eschenbach’s Commissioner Debut May Be Release Of Safety Report
One of Andrew von Eschenbach's first major steps as FDA commissioner is likely to be release of the agency task force response to the Institute of Medicine's recommendations to improve drug safety oversight
FDA considers meeting on Mifeprex
Agency is discussing holding a workshop on Clostridium sordellii after determining that four women who died from sepsis following use of Danco's abortifacient Mifeprex (mifepristone) tested positive for the bacteria. FDA notes that tests of lots of mifepristone (also known as RU-486) and misoprostol (which is used in conjunction with Mifeprex) were negative for contamination. Agency issued a public health advisory July 19 concerning the sepsis deaths (1"The Pink Sheet" July 25, 2005, p. 4)...